| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniela Fonseca de Freitas, Giouliana Kadra-Scalzo, Deborah Agbedjro, Emma Francis, Isobel Ridler, Megan Pritchard, Hitesh Shetty, Aviv Segev, Cecilia Casetta, Sophie E Smart, Johnny Downs, Søren Rahn Christensen, Nikolaj Bak, Bruce J Kinon, Daniel Stahl, James H MacCabe, Richard D Haye. Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine. Journal of psychopharmacology (Oxford, England). 2022-02-25. PMID:35212240. |
a proportion of people with treatment-resistant schizophrenia fail to show improvement on clozapine treatment. |
2022-02-25 |
2023-08-13 |
Not clear |
| Tomoyuki Imai, Sho Ochiai, Takehiro Ishimaru, Hayato Daitoku, Yusuke Miyagawa, Ryuji Fukuhara, Shuken Boku, Minoru Takebayash. A case report: Clozapine-induced leukopenia and neutropenia after mRNA COVID-19 vaccination. Neuropsychopharmacology reports. 2022-02-15. PMID:35166466. |
clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia and is known to cause serious side effects, such as leukopenia and neutropenia. |
2022-02-15 |
2023-08-13 |
Not clear |
| Simon W Rabkin, Jacky K K Tan. Clozapine-Induced Myocarditis: Pathophysiologic Mechanisms and implications for therapeutic approaches. Current molecular pharmacology. 2022-02-14. PMID:35152873. |
clozapine, a superior treatment for otherwise treatment-resistant schizophrenia can produce a potentially life-threatening myocarditis and dilated cardiomyopathy. |
2022-02-14 |
2023-08-13 |
Not clear |
| Manabu Takaki, Yuji Yada, Shinji Sakamoto, Masaki Fujiwara, Yuko Okahisa, Norihito Yamad. A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine. Journal of clinical psychopharmacology. 2022-02-12. PMID:35149611. |
a decrease of neutrophils after covid-19 vaccination in a treatment-resistant patient with schizophrenia taking clozapine. |
2022-02-12 |
2023-08-13 |
Not clear |
| Sandeep Grover, Chandrima Naskar, Subho Chakrabart. Impact of clozapine on disability and course of illness in patients with schizophrenia: A study from North India. Indian journal of psychiatry. vol 63. issue 6. 2022-02-09. PMID:35136257. |
impact of clozapine on disability and course of illness in patients with schizophrenia: a study from north india. |
2022-02-09 |
2023-08-13 |
Not clear |
| Sandeep Grover, Chandrima Naskar, Subho Chakrabart. Impact of clozapine on disability and course of illness in patients with schizophrenia: A study from North India. Indian journal of psychiatry. vol 63. issue 6. 2022-02-09. PMID:35136257. |
the aim of this study was to evaluate the impact of long-term use of clozapine on disability and course of illness among patients with treatment-resistant schizophrenia. |
2022-02-09 |
2023-08-13 |
Not clear |
| Tetsu Tomita, Yui Sakamoto, Manabu Saito, Kojiro Hashimoto, Yasuki Ono, Kazuhiko Nakamur. Two Patients with Schizophrenia Treated with Clozapine Developed Neutropenia After Receiving a COVID-19 Vaccine. International medical case reports journal. vol 15. 2022-02-04. PMID:35115846. |
two patients with schizophrenia treated with clozapine developed neutropenia after receiving a covid-19 vaccine. |
2022-02-04 |
2023-08-13 |
Not clear |
| Tetsu Tomita, Yui Sakamoto, Manabu Saito, Kojiro Hashimoto, Yasuki Ono, Kazuhiko Nakamur. Two Patients with Schizophrenia Treated with Clozapine Developed Neutropenia After Receiving a COVID-19 Vaccine. International medical case reports journal. vol 15. 2022-02-04. PMID:35115846. |
we observed two cases of patients with schizophrenia who were treated with clozapine (250mg/day and 275mg/day, respectively) and showed neutropenia after receiving a covid-19 vaccine (bnt162b2). |
2022-02-04 |
2023-08-13 |
Not clear |
| Ebenezer Oloyede, Ivana Clark, Shubhra Mace, Eromona Whiskey, David Taylo. Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review. Therapeutic advances in psychopharmacology. vol 12. 2022-02-03. PMID:35111297. |
only about 50% of patients with treatment-resistant schizophrenia respond to clozapine, and many more patients continue to experience ongoing and prominent negative symptoms. |
2022-02-03 |
2023-08-13 |
Not clear |
| Siobhan Gee, David Taylo. Alternative Routes of Administration of Clozapine. CNS drugs. 2022-02-03. PMID:35113345. |
clozapine is the only antipsychotic with proven effectiveness in treatment-resistant schizophrenia. |
2022-02-03 |
2023-08-13 |
Not clear |
| J P Lindenmayer, Beverly J Insel, Anzalee Khan, McKenzie Osborne, Abraham Goldring, Mary Sedd. Effects of Clozapine on Neurocognitive Functions in Schizophrenia: A Naturalistic Comparison to Non-clozapine Antipsychotics. Innovations in clinical neuroscience. vol 18. issue 10-12. 2022-01-31. PMID:35096483. |
effects of clozapine on neurocognitive functions in schizophrenia: a naturalistic comparison to non-clozapine antipsychotics. |
2022-01-31 |
2023-08-13 |
Not clear |
| J P Lindenmayer, Beverly J Insel, Anzalee Khan, McKenzie Osborne, Abraham Goldring, Mary Sedd. Effects of Clozapine on Neurocognitive Functions in Schizophrenia: A Naturalistic Comparison to Non-clozapine Antipsychotics. Innovations in clinical neuroscience. vol 18. issue 10-12. 2022-01-31. PMID:35096483. |
this study aimed to compare the neurocognitive effects of clozapine treatment to those of non-clozapine antipsychotics in patients with schizophrenia and to examine the role of anticholinergic burden on cognitive impairments. |
2022-01-31 |
2023-08-13 |
Not clear |
| Mahwish Adnan, Fatima Motiwala, Chintan Trivedi, Tania Sultana, Zeeshan Mansuri, Shailesh Jai. Clozapine for Management of Childhood and Adolescent-Onset Schizophrenia: A Systematic Review and Meta-Analysis. Journal of child and adolescent psychopharmacology. 2022-01-31. PMID:35099269. |
clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis. |
2022-01-31 |
2023-08-13 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Nobuyuki Nomura, Kohei Kitagawa, Yuya Mizuno, Fuminari Misawa, Masafumi Kodama, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuch. Association between subjective distress and symptom domains in patients with treatment-resistant schizophrenia receiving clozapine. Schizophrenia research. vol 240. 2022-01-27. PMID:35086033. |
association between subjective distress and symptom domains in patients with treatment-resistant schizophrenia receiving clozapine. |
2022-01-27 |
2023-08-13 |
Not clear |
| Laurent Béchard, Olivier Corbeil, Marc-André Thivierge, Ibrahim Assaad, Camille Boulanger, Marie-Pierre Mailhot, Alexis Turgeon-Fournier, Marc-André Roy, Marie-France Demer. Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 1. 2022-01-26. PMID:35078963. |
clozapine has a unique efficacy in treatment-resistant schizophrenia. |
2022-01-26 |
2023-08-13 |
Not clear |
| Laurent Béchard, Olivier Corbeil, Marc-André Thivierge, Ibrahim Assaad, Camille Boulanger, Marie-Pierre Mailhot, Alexis Turgeon-Fournier, Marc-André Roy, Marie-France Demer. Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 1. 2022-01-26. PMID:35078963. |
a 20-year-old caucasian male diagnosed with resistant schizophrenia developed, after a 5-month total exposition and a significant response to treatment, a marked creatine kinase (ck) elevation and important myalgia in the weeks following an increment from 175 to 200 mg of the daily dose of clozapine. |
2022-01-26 |
2023-08-13 |
Not clear |
| Xiaoping Yuan, Song Wang, Yudong Shi, Yating Yang, Yulong Zhang, Lei Xia, Kai Zhang, Huanzhong Li. Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine. Psychopharmacology. 2022-01-26. PMID:35080634. |
pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine. |
2022-01-26 |
2023-08-13 |
Not clear |
| Xiaoping Yuan, Song Wang, Yudong Shi, Yating Yang, Yulong Zhang, Lei Xia, Kai Zhang, Huanzhong Li. Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine. Psychopharmacology. 2022-01-26. PMID:35080634. |
the aims of this study were to detect (1) whether serum cytokine levels were altered in patients with chronic schizophrenia after clozapine treatment compared with age- and sex-matched healthy controls, (2) whether there was a gender difference in serum cytokine levels after clozapine treatment, and (3) whether there was a correlation between serum cytokine levels and clozapine daily dosage in patients with schizophrenia. |
2022-01-26 |
2023-08-13 |
Not clear |
| Mark Vickers, Vinay Ramineni, Eva Malacova, Lars Eriksson, Kirsten McMahon, Vikas Moudgil, James Scott, Dan Siskin. Risk factors for Clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis. Acta psychiatrica Scandinavica. 2022-01-24. PMID:35067911. |
clozapine is the most effective medication for treatment refractory schizophrenia; however, it is associated with severe cardiac adverse events including myocarditis and cardiomyopathy. |
2022-01-24 |
2023-08-13 |
Not clear |
| Ruth Cano-Corres, Siddarta Acebillo, Francesc Campos Barreda, Diego J Palao, Eugenio Berlanga-Escaler. Impact of a Novel Strategy for Critical Values Communication for the Management of Patients Treated with Clozapine. EJIFCC. vol 32. issue 4. 2022-01-20. PMID:35046764. |
clozapine is an antipsychotic drug used to treat resistant schizophrenia and other disorders. |
2022-01-20 |
2023-08-13 |
Not clear |